Wedge Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-192,872
| Closed | -$27M | – | 516 |
|
|
2025
Q3 | $27M | Buy |
+192,872
| New | +$26.1M | 0.46% | 82 |
|
|
2025
Q1 | – | Sell |
-179,191
| Closed | -$27.4M | – | 517 |
|
|
2024
Q4 | $27.4M | Buy |
179,191
+26,530
| +17% | +$4.47M | 0.49% | 78 |
|
|
2024
Q3 | $29.6M | Buy |
152,661
+4,147
| +3% | +$868K | 0.51% | 80 |
|
|
2024
Q2 | $34.4M | Sell |
148,514
-33,010
| -18% | -$7.17M | 0.61% | 70 |
|
|
2024
Q1 | $39.1M | Buy |
181,524
+54,036
| +42% | +$12.7M | 0.63% | 69 |
|
|
2023
Q4 | $33M | Buy |
127,488
+9,284
| +8% | +$2.28M | 0.59% | 52 |
|
|
2023
Q3 | $30.4M | Buy |
118,204
+11,389
| +11% | +$3.05M | 0.6% | 65 |
|
|
2023
Q2 | $30.4M | Sell |
106,815
-34,811
| -25% | -$10.4M | 0.48% | 65 |
|
|
2023
Q1 | $39.4M | Buy |
141,626
+7,199
| +5% | +$1.99M | 0.66% | 25 |
|
|
2022
Q4 | $37.2M | Buy |
+134,427
| New | +$38M | 0.6% | 50 |
|
|
2021
Q4 | – | Sell |
-105,756
| Closed | -$29.9M | – | 416 |
|
|
2021
Q3 | $29.9M | Buy |
+105,756
| New | +$34.7M | 0.39% | 98 |
|
|
2020
Q4 | – | Sell |
-100,861
| Closed | -$28.6M | – | 570 |
|
|
2020
Q3 | $28.6M | Sell |
100,861
-28,490
| -22% | -$7.95M | 0.38% | 68 |
|
|
2020
Q2 | $34.6M | Buy |
129,351
+23,745
| +22% | +$7.14M | 0.48% | 67 |
|
|
2020
Q1 | $33.4M | Sell |
105,606
-28,480
| -21% | -$8.64M | 0.58% | 58 |
|
|
2019
Q4 | $39.8M | Sell |
134,086
-24,744
| -16% | -$6.87M | 0.44% | 88 |
|
|
2019
Q3 | $37M | Buy |
158,830
+13,231
| +9% | +$3.08M | 0.43% | 72 |
|
|
2019
Q2 | $34.1M | Buy |
145,599
+25,866
| +22% | +$5.97M | 0.39% | 92 |
|
|
2019
Q1 | $28.3M | Buy |
119,733
+15,344
| +15% | +$4.83M | 0.32% | 101 |
|
|
2018
Q4 | $31.4M | Buy |
104,389
+3,516
| +3% | +$1.12M | 0.39% | 91 |
|
|
2018
Q3 | $35.6M | Sell |
100,873
-1,751
| -2% | -$603K | 0.34% | 86 |
|
|
2018
Q2 | $29.8M | Sell |
102,624
-19,096
| -16% | -$5.37M | 0.29% | 111 |
|
|
2018
Q1 | $33.3M | Sell |
121,720
-17,611
| -13% | -$5.47M | 0.32% | 98 |
|
|
2017
Q4 | $44.4M | Buy |
139,331
+4,248
| +3% | +$1.36M | 0.4% | 77 |
|
|
2017
Q3 | $42.3M | Sell |
135,083
-15,116
| -10% | -$4.48M | 0.39% | 70 |
|
|
2017
Q2 | $40.8M | Sell |
150,199
-7,608
| -5% | -$2.01M | 0.39% | 71 |
|
|
2017
Q1 | $43.1M | Sell |
157,807
-24,751
| -14% | -$7M | 0.41% | 87 |
|
|
2016
Q4 | $51.8M | Buy |
182,558
+23,759
| +15% | +$7.04M | 0.5% | 54 |
|
|
2016
Q3 | $49.7M | Sell |
158,799
-33,978
| -18% | -$10.1M | 0.5% | 57 |
|
|
2016
Q2 | $46.6M | Buy |
+192,777
| New | +$50.8M | 0.48% | 65 |
|
Other funds holding BIIB
Wedge Capital Management's BIIB Position: Q4 2025 in Review
Wedge Capital Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 192,872 shares — an estimated $27M sold.
Wedge Capital Management first reported a position in BIIB in Q2 2016 and held it in 29 quarters. The position peaked at $51.8M in Q4 2016. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.
- Wedge Capital Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
- Wedge Capital Management sold 192,872 Biogen shares in Q4 2025, an estimated $27M.
- Wedge Capital Management first reported a position in Biogen in Q2 2016 and held it in 29 quarters.
- Wedge Capital Management's Biogen position peaked at $51.8M in Q4 2016.
- 997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.
Based on Wedge Capital Management's 13F filing for Q4 2025, filed 14 Jan 2026.